Fibroblast growth factor 21 as a biomarker for NAFLD: integrating pathobiology into clinical practice
- PMID: 20800308
- DOI: 10.1016/j.jhep.2010.07.003
Fibroblast growth factor 21 as a biomarker for NAFLD: integrating pathobiology into clinical practice
Comment on
-
Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride.J Hepatol. 2010 Nov;53(5):934-40. doi: 10.1016/j.jhep.2010.05.018. Epub 2010 Jul 17. J Hepatol. 2010. PMID: 20675007
Similar articles
-
Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease.Clin Biochem. 2012 Jun;45(9):655-8. doi: 10.1016/j.clinbiochem.2012.03.019. Epub 2012 Mar 19. Clin Biochem. 2012. PMID: 22465275
-
Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology.Eur J Gastroenterol Hepatol. 2012 Mar;24(3):255-61. doi: 10.1097/MEG.0b013e32834e8041. Eur J Gastroenterol Hepatol. 2012. PMID: 22157234
-
Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride.J Hepatol. 2010 Nov;53(5):934-40. doi: 10.1016/j.jhep.2010.05.018. Epub 2010 Jul 17. J Hepatol. 2010. PMID: 20675007
-
[Role of liver biopsy in the diagnosis of NASH].Nihon Rinsho. 2006 Jun;64(6):1119-25. Nihon Rinsho. 2006. PMID: 16768119 Review. Japanese.
-
Nonalcoholic fatty liver disease and bariatric surgery.Expert Rev Gastroenterol Hepatol. 2012 Apr;6(2):163-71. doi: 10.1586/egh.11.97. Expert Rev Gastroenterol Hepatol. 2012. PMID: 22375522 Review.
Cited by
-
Liver-bone crosstalk in non-alcoholic fatty liver disease: Clinical implications and underlying pathophysiology.Front Endocrinol (Lausanne). 2023 Mar 10;14:1161402. doi: 10.3389/fendo.2023.1161402. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36967758 Free PMC article. Review.
-
Fibroblast growth factor 21 levels and liver inflammatory biomarkers in obese subjects after weight loss.Arch Med Sci. 2021 Mar 18;18(1):36-44. doi: 10.5114/aoms/98948. eCollection 2022. Arch Med Sci. 2021. PMID: 35154523 Free PMC article.
-
Pathophysiology of NASH in endocrine diseases.Endocr Connect. 2021 Feb;10(2):R52-R65. doi: 10.1530/EC-20-0490. Endocr Connect. 2021. PMID: 33449917 Free PMC article. Review.
-
FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human.Front Endocrinol (Lausanne). 2020 Dec 22;11:601349. doi: 10.3389/fendo.2020.601349. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33414764 Free PMC article. Review.
-
Including Fibroblast Growth Factor-21 in Combined Biomarker Panels Improves Predictions of Liver Steatosis Severity in Children.Front Pediatr. 2019 Oct 30;7:420. doi: 10.3389/fped.2019.00420. eCollection 2019. Front Pediatr. 2019. PMID: 31750276 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources